Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anthrax Vaccines
PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
October 1st, 2008
PharmAthene, Inc. (AMEX:PIP) a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced that it has received notification from the Department of Health and Human Services (DHHS) that the Company's proposal for its recombinant protective antigen anthrax vaccine, SparVax(TM), has completed a comprehensive technical and business evaluation by DHHS and has been deemed to be technically acceptable and within the competitive range. The negotiation phase for a development and procurement contract is now underway. DHHS has stated that it intends to make an award under the solicitation by end of the...
Source: Vaccine Weekly (2008-10-01)
|
|
Advertisement |
|
|
|
